$YARW

Biotech shares hit 52-week highs on Aug. 3-4, 2026, led by catalysts including upcoming quarterly reports and clinical-trial updates. AngioDynamics (ANGO) reached $15.41, citing FDA clearance for its RELIEF study and FY2026 net sales of $320.2 million. Anika (ANIK) hit $21.11 after Q2 revenue rose to $32.6 million. Pulse (PLSE) rose to $38.29 ahead of Aug. 6 results; Eloxx (ELOX) and Yarrow (YARW) also reached highs.

Yarrow Bioscience (VYNE) holder swaps 133K shares for warrants Rhea-AI Filing Summary Yarrow Bioscience, Inc. reports that an affiliated RTW Entity managed by RTW Fund Group GP, LLC exchanged 133,290 shares of common stock for pre-funded warrants to purchase the same number of shares on July 29, 2026.

Yarrow Bioscience, Inc. (VYNE) holders report 8,816,429 pre-funded warrants Rhea-AI Filing Summary RTW Fund Group GP, LLC and Roderick Wong, M.D., reported as ten percent owners of Yarrow Bioscience, Inc., disclose indirect holdings received in a July 27, 2026 merger: 399,597 shares of common stock and pre-funded warrants exercisable at $0.0001 for 8,816,429 shares, subject to a 9.99% beneficial ownership cap.

RTW Biotech Opportunities said Yarrow Bioscience completed its merger with VYNE Therapeutics, alongside about $200m in private financings led by RTW. The combined company began Nasdaq trading as Yarrow Bioscience under ticker YARW. YB-101 received FDA Fast Track; Phase 2a data are expected in 2H 2027.

Yarrow Bioscience, Inc. (VYNE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-3.5 6 tm2620687d3_ex3-5.htm EXHIBIT 3.5 Exhibit 3.5 AMENDED AND RESTATED BYLAWS OF YARROW BIOSCIENCE, INC. (a Delaware corporation) Article I CORPORATE OFFICES Section 1.1 Registered Office . The registered office of Yarrow Bioscience, Inc., a Delaware corporation (the “ Corpo

VYNE Therapeutics said it distributed a special cash dividend to holders of record July 22, 2026, paid July 23, subject to Nasdaq due bill procedures, ahead of a planned 1-for-50 reverse split effective July 24 and split-adjusted trading July 27. VYNE expects merger closing with Yarrow Bioscience early in the week of July 27, with the combined company trading as YARW. VYNE closed at $0.9234.

VYNE Therapeutics said its board approved a 1-for-50 reverse stock split ahead of its merger with Yarrow Bioscience. VYNE shares would fall from about 33.4M to 0.7M. After the merger, trading is expected to start July 27, 2026 as Yarrow Bioscience (YARW). A $17.3M special cash dividend, about $0.40242 per share, is payable to holders of record July 22.

VYNE Therapeutics (VYNE) said its board approved a 1-for-50 reverse stock split tied to its planned merger with Yarrow Bioscience. The split should cut shares from about 33.4M to about 0.7M. The merger is expected to close July 24, 2026, with the combined firm trading July 27 as Yarrow Bioscience (YARW). VYNE also set a special dividend of about $0.40242 per share.

VYNE Therapeutics (Nasdaq: VYNE) said its board approved a 1-for-50 reverse stock split ahead of its proposed merger with Yarrow Bioscience. After the merger, trading is expected to start July 27 under Yarrow Bioscience (Nasdaq: YARW). VYNE also updated a $17.3 million special cash dividend, about $0.40242 per share, with due bill rules around the record and payment dates.

VYNE Therapeutics Inc. (VYNE) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001566044 0001566044 2026-07-16 2026-07-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor